Core Insights - The insomnia medication market in China is experiencing a resurgence with new products being approved after a long hiatus, indicating increasing competition among both new and existing drugs [2][4][5] - The market size for insomnia medications in China was 12.28 billion yuan in 2021, projected to reach 15.12 billion yuan by 2025 and 21.19 billion yuan by 2030, highlighting significant growth potential [3][7] Company Developments - Xiansheng Pharmaceutical plans to invest 30 million yuan over the next three years in an open research initiative for new insomnia drugs, inviting external participants to collaborate on research projects [2][6] - The newly approved drug Dali Leisheng by Xiansheng Pharmaceutical is a dual orexin receptor antagonist, marking a significant advancement in insomnia treatment options [5][6] Industry Trends - The prevalence of insomnia in China is high, with an estimated 38.2% of adults affected, leading to increased focus on sleep health and the demand for effective treatments [3][7] - The insomnia drug market has evolved through four generations, with the latest generation focusing on orexin receptor antagonists, which offer a novel mechanism of action compared to traditional sedatives [3][4] Competitive Landscape - The approval of new insomnia medications, such as Dali Leisheng and Jiyin Pharmaceutical's innovative drug, is intensifying competition in the market, with companies actively promoting their products [5][7] - The market is currently dominated by second-generation drugs like Midazolam, while newer fourth-generation drugs are still in the early stages of commercialization [5][6]
新药搅动抗失眠药百亿赛道，先声药业斥3000万元用于开放课题研究